- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
- Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
- Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Announces Updates to Operations Leadership
- Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
- Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
- Liquidia Corporation Announces $100 Million in New Financings
More ▼
Key statistics
On Wednesday, Liquidia Corp (LQDA:NAQ) closed at 13.17, -22.48% below its 52-week high of 16.99, set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.85 |
---|---|
High | 13.42 |
Low | 12.85 |
Bid | 13.20 |
Offer | 13.50 |
Previous close | 13.17 |
Average volume | 904.44k |
---|---|
Shares outstanding | 76.03m |
Free float | 66.60m |
P/E (TTM) | -- |
Market cap | 1.00bn USD |
EPS (TTM) | -1.21 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼